389 related articles for article (PubMed ID: 34145037)
1. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.
Tsao LC; Force J; Hartman ZC
Cancer Res; 2021 Sep; 81(18):4641-4651. PubMed ID: 34145037
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment.
Saini S; Gulati N; Awasthi R; Arora V; Singh SK; Kumar S; Gupta G; Dua K; Pahwa R; Dureja H
Curr Drug Deliv; 2024; 21(7):993-1009. PubMed ID: 37519200
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB.
Manso T; Kushwaha A; Abdollahi N; Duroux P; Giudicelli V; Kossida S
Front Immunol; 2023; 14():1129323. PubMed ID: 37215135
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.
Paci A; Desnoyer A; Delahousse J; Blondel L; Maritaz C; Chaput N; Mir O; Broutin S
Eur J Cancer; 2020 Mar; 128():107-118. PubMed ID: 32037061
[TBL] [Abstract][Full Text] [Related]
5. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
Marrocco I; Romaniello D; Yarden Y
Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
[TBL] [Abstract][Full Text] [Related]
6. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy.
Zhou K; Hong H; Lin H; Gong L; Li D; Shi J; Zhou Z; Xu F; Wu Z
J Med Chem; 2022 Jan; 65(1):323-332. PubMed ID: 34962121
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapy With Immunoconjugates for Multiple Myeloma.
Bruins WSC; Zweegman S; Mutis T; van de Donk NWCJ
Front Immunol; 2020; 11():1155. PubMed ID: 32636838
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors.
Charmsaz S; Scott AM; Boyd AW
Exp Hematol; 2017 Oct; 54():31-39. PubMed ID: 28751189
[TBL] [Abstract][Full Text] [Related]
9. The impact of thioredoxin reduction of allosteric disulfide bonds on the therapeutic potential of monoclonal antibodies.
Gurjar SA; Wheeler JX; Wadhwa M; Thorpe R; Kimber I; Derrick JP; Dearman RJ; Metcalfe C
J Biol Chem; 2019 Dec; 294(51):19616-19634. PubMed ID: 31727737
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes.
Mishra RK; Ahmad A; Vyawahare A; Kumar A; Khan R
Curr Top Med Chem; 2020; 20(20):1810-1823. PubMed ID: 32543361
[TBL] [Abstract][Full Text] [Related]
11. The next generation of antibody-drug conjugates comes of age.
Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors.
Li XF; Liu CF; Rao GW
Curr Med Chem; 2021; 28(17):3339-3360. PubMed ID: 32900344
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates.
Hasan MM; Laws M; Jin P; Rahman KM
Drug Discov Today; 2022 Jan; 27(1):354-361. PubMed ID: 34597756
[TBL] [Abstract][Full Text] [Related]
14. Anti-body building: The exercise of advancing immune based myeloma therapies.
Richter J; Thibaud S
Blood Rev; 2021 Jul; 48():100789. PubMed ID: 33384171
[TBL] [Abstract][Full Text] [Related]
15. A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors.
Aghanejad A; Bonab SF; Sepehri M; Haghighi FS; Tarighatnia A; Kreiter C; Nader ND; Tohidkia MR
Int J Biol Macromol; 2022 May; 207():592-610. PubMed ID: 35296439
[TBL] [Abstract][Full Text] [Related]
16. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?
Mir O; Broutin S; Desnoyer A; Delahousse J; Chaput N; Paci A
Eur J Cancer; 2020 Mar; 128():103-106. PubMed ID: 32089494
[TBL] [Abstract][Full Text] [Related]
18. [Design of next generation antibody drug conjugates].
Zhu GD; Fu YX
Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
[TBL] [Abstract][Full Text] [Related]
19. Fate of Antibody-Drug Conjugates in Cancer Cells.
Chalouni C; Doll S
J Exp Clin Cancer Res; 2018 Feb; 37(1):20. PubMed ID: 29409507
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a reporter gene assay to determine the bioactivity of anti-CTLA-4 monoclonal antibodies.
Liu C; Yu C; Yang Y; Cui Y; Zhang F; Wang L; Wang J
Int Immunopharmacol; 2021 Dec; 101(Pt A):108277. PubMed ID: 34773758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
